Valuation: Arcutis Biotherapeutics, Inc.

Market Cap 3.25B 2.81B 2.64B 2.41B 4.53B 310B 4.6B 31.06B 12.13B 155B 12.19B 11.92B 517B P/E 2026 *
66.5x
P/E 2027 * 20.7x
Enterprise Value 2.96B 2.56B 2.4B 2.19B 4.12B 282B 4.19B 28.3B 11.05B 141B 11.11B 10.87B 471B EV / Sales 2026 *
5.51x
EV / Sales 2027 * 3.81x
Free-Float
98.22%
Yield 2026 *
-
Yield 2027 * -
1 day-1.71%
1 week-2.27%
Current month-3.83%
1 month-4.76%
3 months+19.09%
6 months-0.12%
Current year-11.05%
1 week 24.76
Extreme 24.76
26.82
1 month 24.76
Extreme 24.76
29.24
Current year 19.3
Extreme 19.295
30.75
1 year 15.1
Extreme 15.1
31.77
3 years 1.76
Extreme 1.76
31.77
5 years 1.76
Extreme 1.76
31.77
10 years 1.76
Extreme 1.76
40.88
Manager TitleAgeSince
Chief Executive Officer 58 31/03/2017
Corporate Officer/Principal 71 02/12/2025
Director of Finance/CFO - 14/05/2025
Director TitleAgeSince
Chairman 55 30/11/2019
Director/Board Member 58 31/12/2015
Director/Board Member 74 31/07/2020
Date Insider Type Main position Quantity % Market Cap.
03/08/26 Sell

Chief Technology Officer

-955 0.0008%
03/08/26 Sell

General Counsel

-1,230 0.0010%
03/08/26 Sell

Chief Executive Officer

-4,375 0.0035%
Change 5-day change 1-year change 3-year change Capi.($)
-1.71%-2.27%+65.26%+188.28% 3.25B
+1.00%+4.39%+43.53%-0.12% 80.48B
+0.97%+3.30%-2.19%+26.99% 51.06B
-2.19%-3.90%+10.34%+161.02% 48.19B
-0.74%+3.26%-49.46%-48.10% 46.5B
+0.85%+2.12%+55.82%-23.03% 31.12B
-0.03%+18.18%+136.71%-37.28% 25.41B
-0.21%+1.81%+40.38%+82.80% 24.43B
-1.42%-1.11%-2.29%+189.51% 21.11B
-2.41%-3.13%+61.40%+104.95% 16.28B
Average -0.59%+3.13%+35.95%+64.50% 34.78B
Weighted average by Cap. -0.19%+3.18%+25.73%+39.02%

Financials

2026 *2027 *
Net sales 537M 465M 436M 398M 749M 51.25B 761M 5.14B 2.01B 25.65B 2.02B 1.97B 85.57B 686M 594M 557M 508M 956M 65.43B 971M 6.56B 2.56B 32.75B 2.57B 2.52B 109B
Net income 51.79M 44.89M 42.08M 38.37M 72.2M 4.94B 73.36M 496M 193M 2.47B 194M 190M 8.25B 168M 146M 136M 124M 234M 16.02B 238M 1.61B 627M 8.02B 630M 617M 26.76B
Net Debt -288M -250M -234M -214M -402M -27.52B -408M -2.76B -1.08B -13.78B -1.08B -1.06B -45.96B -638M -553M -518M -473M -889M -60.87B -903M -6.1B -2.38B -30.47B -2.39B -2.34B -102B
Logo Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company develops therapies against biologically validated targets and produces a pipeline for a range of inflammatory dermatological conditions. Its portfolio consists of topical and systemic treatments to treat immune-mediated dermatological diseases and conditions. Its product portfolio includes ZORYVE Roflumilast Cream, ZORYVE Roflumilast Foam, and ARQ-234. The ZORYVE Roflumilast Cream is used for the treatment of seborrheic dermatitis in individuals aged 9 years and older. The ZORYVE Roflumilast Foam for the topical treatment of mild to moderate atopic dermatitis in adults and pediatric patients 6 years of age and older. The ARQ-234 is a fusion protein that is a checkpoint agonist of the CD200 Receptor (CD200R). CD200R is an immune-regulatory receptor which is an immunological checkpoint with a role in the maintenance of immune tolerance.
Employees
354
Date Price Change Volume
13/08/26 US$25.83 -1.71% 1,585,686
12/08/26 US$26.28 +0.19% 1,184,073
11/08/26 US$26.23 +1.20% 1,050,003
10/08/26 US$25.92 +2.49% 2,094,918
07/08/26 US$25.29 -4.31% 2,449,133
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
25.83USD
Average target price
36.88USD
Spread / Average Target
+42.76%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ARQT Stock